Skip links

Pipeline powered by groundbreaking glyco targeting engine

GO Therapeutics’ platform is continually generating new solid tumor targets, feeding a growing pipeline of novel cancer immuno-therapies.

ANTIBODY PROGRAM

MODALITIES

INDICATIONS

Mucins

GO-2

TCB

Solid Tumors     

ANTIBODY PROGRAM

GO-2

MODALITIES

TCB

INDICATIONS

Solid Tumors     

GO-2D5

TCB

Solid Tumors

ANTIBODY PROGRAM

GO-2D5

MODALITIES

TCB

INDICATIONS

Solid Tumors

Receptor Proteins

GO-4C8

CAR-T

Solid Tumors

ANTIBODY PROGRAM

GO-4C8

MODALITIES

CAR-T

INDICATIONS

Solid Tumors

GO-14C9

TCB

Solid Tumors

ANTIBODY PROGRAM

GO-14C9, GO-8H3

MODALITIES

CAR-T, TCB

INDICATIONS

Solid Tumors

GO-8H3

CAR-T

Lysomal

GO-3C7

ADC

Solid Tumors

ANTIBODY PROGRAM

GO-3C7

MODALITIES

ADC

INDICATIONS

Solid Tumors

ECM

GO-C15

Immunokine

Solid Tumors

ANTIBODY PROGRAM

GO-C15

MODALITIES

Immunokine

INDICATIONS

Solid Tumors